Table 1.
The IC50 values of infecting viruses and viral shedding characteristics of ferrets dosed with either placebo or oseltamivir.
Table 2.
The clinical score card used to determine severity of clinical signs in ferrets infected with influenza viruses.
Table 3.
Severity of clinical signs in ferrets infected with influenza viruses.
Fig 1.
Viral shedding data from ferrets exposed to different viruses and dosed with either OST or Placebo.
The data for all ferrets are shown after standardising to first day of TCID50 positive, as this day varied between different ferrets, and each individual ferret within a group is identified by a separate colour. The variability in first day of viral shedding is summarised in S2 Fig. The bar graphs represent the mean viral titre for all ferrets within the group on each day. The B stands for baseline.
Fig 2.
A scatter plot showing the relationship between %ΔAUC (difference between placebo and OST dosed animals) of viral shedding of ferrets and the OST IC50.
This graph shows the significant correlation between in vitro OST IC50 and in vivo effect on viral shedding. The regression model reveals the following relationship where y = e4.35–0.03x. The shaded region of the graph is the 95% confidence interval of the line of best fit, calculated by bootstrapping over 2500 iterations.
Fig 3.
Influenza virus titres from nasal washes and tracheal lavages from macaques infected with either H1N1pdm09 or H1N1pdm09 (H275Y) virus and treated with either OST or placebo.
Three macaques were allocated per group and artificially infected with 106 TICD50/ml of viral inoculum. No significant differences were observed in viral titre between animals treated with OST compared to those treated with placebo. Panel a) shows viral titre data from nasal washes of animals and b) shows viral tire data from tracheal lavages.